Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals Price Performance
Shares of NASDAQ:AMLX opened at $25.50 on Wednesday. The firm has a fifty day moving average price of $19.64 and a two-hundred day moving average price of $17.95. Amylyx Pharmaceuticals has a one year low of $6.51 and a one year high of $33.41.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.18). Sell-side analysts forecast that Amylyx Pharmaceuticals will post -3.55 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Citigroup raised their price target on Amylyx Pharmaceuticals from $33.00 to $37.00 and gave the stock a "buy" rating in a report on Wednesday, July 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $39.50.